News

The data from CVBT’s Phase II trial suggested that CVBT’s FGF-1 biological drug showed efficacy at a level greater than has been seen in any other treatments, for

As per the terms of the agreement, ImmunGene is entitled to get undisclosed fees which include upfront payment from Cephalon Australia a four-year option to leverage ImmunGene’s novel

Under the pact, Kinaxo will make use of high-end mass spectrometry-based technologies to quantitatively evaluate posttranslational protein modifications on a proteome-wide scale. Kinaxo CTO Henrik Daub said that

The original agreement was signed in January 2009 between Santaris Pharma and Wyeth, which was acquired by Pfizer. As per the terms of the extended agreement, Santaris Pharma

As per the terms of the agreement, arGEN-X expects to develop new human monoclonal antibody (mAb) candidates that act on various functional sites on Lilly targets. However, Lilly

Prior to its decision, FDA has completed the review of a submission dated 12 November 2010 which provided a Complete Response to the Agency’s reasons for continuing this

Under the agreement, Servier will pay around $35m as an upfront payment and, approximately $470m of milestone payment and tiered royalties. The agreement gives development and commercialization rights

As per the terms of the agreement, Elis has gained commercialization and marketing rights for Vitaros in the Gulf Countries and part of the Middle East (including, Lebanon,

The blinded, placebo-controlled, escalating-dose will enroll 100 healthy adults 18 to 49 years old, who will be grouped into four cohorts and randomised to receive either vaccine treatment